Insiders who reported open-market trades in the last 12 months at the companies Thomas Desrosier files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Matthew R. Henn - $23K in MCRB purchases and sales in the last 12 months
Teresa L. Young - $19K in MCRB purchases and sales in the last 12 months
Eric D. Shaff - $9K in MCRB purchases and sales in the last 12 months
Kelly Brady - $735 in MCRB purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Thomas Desrosier is a corporate insider, tracked as EVP and Chief Legal Officer of Seres Therapeutics, Inc. (MCRB). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Thomas Desrosier submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Thomas Desrosier been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($8K) across all tracked filings.
Thomas Desrosier is EVP and Chief Legal Officer of Seres Therapeutics, Inc. (MCRB). 9 SEC Form 4 filings on record going back to 2024, most recently on 18 August 2026. Most recent open-market trade: sold $373 of MCRB on 18 August 2026. Lifetime open-market sales: $8K.
Recent transactions
16
The latest 16 SEC Form 4 transactions reported by Thomas Desrosier.
InsiderAlpha's records for Thomas Desrosier go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. 23 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
